AzTrials
AzTrials

OsteoarthritisPhase 4NCT00830830

TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis

A Phase 4 study testing Hyalgan (sodium hyaluronate) in people with Osteoarthritis, run by Sanofi at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This extended study will evaluate the efficacy and safety of intra-articular injections of 20mg/2ml dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Osteoarthritis
What is being tested?
Hyalgan (sodium hyaluronate)
How many people
40 participants
Where
1 siteUnited States
Study dates
Dec 2005to Oct 2006
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients having given their written informed consent, prior to participating in the trial.
  • Patients of either sex >= 40 years of age and of sufficient good health that they will be able to complete the 6-month follow-up.
  • Patients with signs and symptoms of osteoarthritis of at least one knee:
  • Diagnosed according to ACR criteria.
  • Based upon a knee X-ray performed within 6 months prior to Screening, the radiograms must be classified as a Grade II or III for osteoarthritis of the knee according to the Kellgren \& Lawrence grading system based upon a radiologist's written report or individual certified for reading knee radiograms. (Sharpening of the tibial spine is not considered to be an osteophyte).
  • Patients with symptoms consistent with osteoarthritis of the knee for at least 6 months prior to Screening. These symptoms must include knee joint pain, and may include crepitus, swelling and/or effusion of the knee.
Show all 15Show fewer
  • At Screening, patients on any analgesic/anti-inflammatory medication should have a visual analogue scale (VAS) pain score after walking on a 50 ft flat surface of > 30 mm but < 90 mm using a 100 mm scale. If patients are not taking any analgesic/anti-inflammatory medication or have not taken any pain medication (prescription [Rx] or over-the-counter [OTC]) in the previous 3 days from Screening then they should have a VAS pain score after walking on a 50 ft flat surface of > 40 mm but < 90 mm. If bilateral knee pain is present, the investigator will select the more painful knee.
  • At Screening and Baseline, if there is bilateral OA of the knee involvement, patients must have a VAS pain score for walking on a 50 ft flat surface of < 30 mm in the less painful contralateral knee at the Baseline assessment. A patient scoring an acceptable VAS pain score at Screening but failing to meet the inclusion and exclusion criteria at Baseline can not be randomized and enrolled.
  • At Baseline, after all analgesic/anti-inflammatory medications have been discontinued for 2 weeks (withdrawal from acetaminophen rescue medication for at least 24 hours prior to Baseline assessment), patients should have a VAS pain score of > 40 mm but < 90 mm immediately after the 50-foot walk on a flat surface. Again, if bilateral knee pain is present, the investigator will select the more painful knee and the contralateral knee must have a VAS pain score of < 30 mm.
  • Patients must have had knee pain in the signal knee on at least 50% of the days in the month preceding Screening.
  • Patients who are able to complete efficacy measurement questionnaires and can understand and read English or Spanish (Spanish forms will be provided).
  • Patients who can perform the 50-foot walk test without the support of crutches or other assistive devices, except for canes. If patient uses a cane routinely in daily activities, then they can use it for their assessments. However, this use must remain stable for all assessments.
  • Minimum flexion of 90 degrees in both knees.
  • Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition, including their knee pain with the exception of acetaminophen, up to 1000 mg (2 tablets) four times a day (q.i.d.), as needed (p.r.n.) (maximum 8 tablets or 4 grams per day). These patients must be willing to use only acetaminophen as a rescue pain medication for the knee pain during the study period and refrain from even acetaminophen use 24 hours prior to any office visit. All other analgesic medications for any chronic condition must be stopped (see exceptions for acute treatment of transient flares of pain). Patients must also be willing to abstain from any intra-articular (i.a.) or peri-articular injections to the knee or surgery during the course of the trial, except for the assigned study product.
  • Patients who, if they are currently taking low dose aspirin (325 mg/day or less), are willing to remain on a stable dose throughout the study and are willing to refrain from any aspirin dose 24 hours prior to any office visit.

Who cannot join

  • Women of childbearing potential may not be entered if:
  • their pregnancy tests (urine test) are positive,
  • they are nursing,
  • they do not use an effective method of contraception until all follow-up procedures are complete. (Methods of contraception considered effective are an oral, injectable or implanted contraceptive agent, or an intra-uterine device with a failure rate of 1% per year, and abstinence).
  • Patients participating in an experimental drug/device study or any clinical trial within the previous 30 days prior to Screening.
  • Patients with a prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening, unless specific permission/waiver by the Sponsor is granted.
Show all 54Show fewer
  • Patients having significant bleeding diathesis.
  • Patients that are currently under litigation for injuries related to the study knee or other injuries that might interfere with their completion of the study protocol.
  • Musculoskeletal Related
  • Patients having any major injury (including sports) to the study knee in past 12 months.
  • Patients having any surgery to the study joint within the previous 12 months prior to Screening, and surgery to the contralateral knee or other weight-bearing joint if it would interfere with the study assessments.
  • Patients having significant surgery of lower limbs (hip, ankle, foot) that may interfere with knee assessments.
  • Patients receiving any articular procedures, such as transplants, to the study knee.
  • Patients having a ligament reconstruction to the study knee.
  • Patients with inflammatory arthropathies such as rheumatoid arthritis, lupus, or psoriatic arthritis
  • Patients with gout or calcium pyrophosphate (pseudogout) diseases that had flared within the previous 6 months prior to Screening.
  • Patients receiving any intra-articular or local peri-articular corticosteroid injections to the study joint/knee within the previous 3 months prior to Screening.
  • Patients receiving any intra-articular, intra-muscular or local peri-articular corticosteroid injections to any other joint (beside the study joint) or soft tissue area within the past 3 months.
  • Patients receiving any oral corticosteroid within the previous month. Steroid inhalants are permitted if the patient has been on a stable regimen for the past month prior to Screening and remains on this regimen throughout the course of the trial.
  • Patients receiving an intra-articular hyaluronan in the study joint within the previous 9 months prior to screening.
  • Patients receiving an intra-articular hyaluronan in any joint within the previous 6 months prior to screening.
  • Patients with a history of allergic reaction to an intra-articular injection or avian products.
  • Patients taking unstable doses of glucosamine- or chondroitin sulfate-containing compounds, or patients taking stable dose for less than 4 months prior to Screening, or patients taking stable dose for at least 4 months prior to and unwilling to remain on these stable doses throughout the course of the trial.
  • Patients on unstable doses of bisphosphonate or patients on stable doses for the past month prior to Screening, and are unwilling to remain on these stable doses throughout the course of the trial.
  • Patients who cannot perform the 50-foot walk test without the support of crutches or other assistive devices, except for canes. If patient uses a cane routinely in daily activities, then they can use it for their clinical assessments. If the patient uses a cane for their Baseline assessment then they must use the cane for ALL subsequent assessments.
  • Patients with X-ray findings of acute fractures, severe loss of bone density, avascular necrosis and/or severe bone or joint deformity.
  • Patients with significant axial deviation of the knee.
  • Patients with OA that is dominantly in the lateral compartment or any significant valgus deformity
  • Patients with significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia.
  • Patients with symptomatic osteoarthritis of either hip, contralateral knee or spine that may interfere with functional assessment of the signal knee.
  • Patients with clinically significant medio-lateral and/or anterior-posterior instability.
  • Patients with osteonecrosis of either knee.
  • Patients that are receiving or performing physical therapy regimen during the previous month from Screening, and/or will not or cannot maintain a stable physical therapy regimen throughout the course of the trial.
  • Patients with Kellgren-Lawrence Grade IV OA (i.e., large osteophytes, marked narrowing, severe sclerosis, and definite deformity) and Grade I OA of the knee.
  • Patients having any arthrogram of the signal joint within the past 3 months prior to Screening.
  • Patients with a hemiparesis of the lower limbs
  • Patients with active liver or renal disease based upon liver profile of SGOT > 2 x ULN (upper limit of normal), and/or conjugated bilirubin > 2 x ULN, and/or renal insufficiency (serum creatinine < 2.0 mg/dL, and/or any clinically significant laboratory value based on clinical history which the investigator feels may affect the evaluation of the patient.
  • Concomitant conditions, diseases, medications and/or clinical history
  • Patients requiring chronic use of analgesia for pain (including pain in the other knee or any other joint) that may interfere with the evaluations of the test knee (such as possible use of rescue medication for these other conditions).
  • Patients with known allergies to acetaminophen, lidocaine, hyaluronans, or avian products.
  • Patients with a recurrent medical history of severe allergic or immune-mediated reactions.
  • Patients with active infection of the skin near the potential injection site.
  • Patients with any dermatological disease overlying the signal joint that would contraindicate multiple injections or aspirations.
  • Patients taking any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug (e.g. doxycycline, long-term tetracycline, s-adenosylmethionine [SAM], dimethyl sulfoxide [DMSO], dietary supplements or any herbal remedy taken for arthritic and joint conditions within the past month. Exceptions are products containing glucosamine/Chondroitin/ methylsulfonylmethane (MSM) if stable for 4 months prior to Screening and remain stable throughout study and fulfill the VAS pain entry criteria).
  • Patients with peripheral neuropathy that would be severe enough to interfere with the evaluation of the patient.
  • Patients with vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the patient.
  • Patients on concomitant therapy with anticoagulants (low dose aspirin, not exceeding 325 mg per day as an anti-thrombotic agent is permitted if stable for one month prior to Screening and remains stable throughout the study.
  • Patients with any inter-current disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 6 month course of the trial (cancer, other rheumatic diseases, gout, severe congenital defects, etc.).
  • Patients with any inter-current chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6 month follow-up of the study such as peptic ulcer, liver disease, severe coronary disease, renal disease, cancer, pregnancy, alcoholism, drug abuse, mental state, or other clinically significant condition.
  • Patients with excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.
  • Patients with any known current addiction to pain medications.
  • Patients that have, in the opinion of the clinical investigator, a clinically significant diagnostic test and/or abnormal laboratory test result(s) that may place the patient at a health risk, impact the study, or affect the patient's ability to complete the study.
  • Patients unable to or with any psychiatric illness that would prevent them to legally comprehend the details and nature of the study.
  • Patients who in the judgment of the clinician are likely to violate the protocol regulations or unlikely to complete the study for any reason.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Sanofi-Aventis Inc

    Bridgewater, New Jersey, 08807

Other trials in United States

About this study

Official title: A Double-Blind, Randomized Trial of Intra-Articular Injections of 20mg of Hyalgan for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection Regimen for Efficacy and Duration - 20mg/2ml Dose) - Extension Study

This extended study will evaluate the efficacy and safety of intra-articular injections of 20mg/2ml dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee.

Conditions
Osteoarthritis
Being tested
Hyalgan (sodium hyaluronate)
Medical subject headings
Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Hyalgan (sodium hyaluronate)Drug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in pain due to OA of the knee after 50-foot walk on a flat surface based upon 100 mm VAS score for up to 6 months after Baseline for the HYALGAN treated group compared to PB-Saline control

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2009 (estimated)
  2. Study startDec 2005
  3. Study completionOct 2006

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00830830
Sponsor's protocol ID
L_9385EXT
Status last verified
Mar 2009
First submitted
21 Jan 2009
Last updated
19 Mar 2009
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Hyalgan (sodium hyaluronate) in people with Osteoarthritis, run by Sanofi at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 54 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Mar 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in pain due to OA of the knee after 50-foot walk on a flat surface based upon 100 mm VAS score for up to 6 months after Baseline for the HYALGAN treated group compared to PB-Saline control. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00830830.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2009.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in